Estrategias terapéuticas para Helicobacter pylori en Colombia

Autores/as

DOI:

https://doi.org/10.21615/cesmedicina.6224

Palabras clave:

Helicobacter pylori, tratamiento, gastritis, cáncer gástrico, Colombia

Resumen

El amplio espectro de enfermedades causadas por la infección Helicobacter pylori obliga a un diagnóstico oportuno y dar un tratamiento altamente eficaz, reduciendo el riesgo de morbilidad y aumentando la probabilidad de erradicación. Son varias las terapias que tienen respaldo en la literatura, por lo que se deben conocer sus ventajas y limitaciones, incluyendo las resistencias bacterianas locales y seleccionar la mejor opción. Este artículo revisa los esquemas de tratamiento más utilizados y ofrece pautas para el manejo y seguimiento del paciente con infección por Helicobacter pylori en Colombia.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Nicolás Zuluaga Arbelaez, Universidad CES

Residente del posgrado de Medicina Interna, Universidad CES, Medellín, Colombia. 

Elsy Cristina Sierra-Vargas, Hospital Pablo Tobón Uribe

Médica internista, Hospital Pablo Tobón Uribe, Medellín, Colombia. 

Luis Gonzalo Guevara-Casallas, Clínica CES

Médico Gastroenterólogo, Clínica CES, Medellín, Colombia. 

Santiago Pérez-Viana, EPS Sura

Médico Gastroenterólogo, EPS Sura, Medellín, Colombia. 

Referencias bibliográficas

Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control. 2013;24(2):209–15.

Graham D. Helicobacter pylori update: Gastric Cancer, Reliable Therapy, and Possible Benefits. Gastroenterology. 2015;148(4):719-731.e3.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021.

Bauerfeind P, Garner R, Dunn BE, Mobley HL. Synthesis and activity of Helicobacter pylori urease and catalase at low pH. Gut. 1997;40(1):25–30.

Perry S, de la Luz Sanchez M, Yang S, Haggerty TD, Hurst P, Perez-Perez G, et al. Gastroenteritis and transmission of Helicobacter pylori infection in households. Emerg Infect Dis. 2006;12(11):1701–8.

Kotilea K, Bontems P, Touati E. Epidemiology, diagnosis and risk factors of Helicobacter pylori Infection. Adv Exp Med Biol. 2019;1149:17–33.

Otero R W, Trespalacios R AA, Otero PL, Vallejo MT, Torres Amaya M, Pardo R et al . Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Colombde Gastroent. 2015. (30.1): 17-33.

Patel KA, Howden CW. Update on the diagnosis and management of Helicobacter pylori infection in adults. J Clin Gastroenterol. 2015;49(6):461–7.

Chey WD, Leontiadis GI, Howden CW, Moss SF. Correction: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018;113(7):1102.

Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.

Otero R W, Gómez Z M, Otero P L, Trespalacios R A. Helicobacter pylori: ¿cómo se trata en el 2018? Rev Gastroenterol Peru. 2018;38(1):54–63.

Crowe SE. Helicobacter pylori infection. Reply. N Engl J Med. 2019;381(6):588–9.

W DB, G T. Review: The Best Therapy for Helicobacter pylori Infection: Should efficacy or side-effect profile determine our choice? Scand J of Gastroent. 1995;30(5).

Gisbert JP, González L, Calvet X, García N, López T, Roqué M, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori: a meta-analysis of h. pylori eradication therapy. Aliment Pharmacol Ther. 2000;14(10):1319–28.

Luther J, Higgins PDR, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65–73.

Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J. 2012;53(4):273–6.

Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori Infection. Digestion. 2013;88(1).

Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori: meta-analysis: effect of antibiotic resistance on treatments for H. pylori. Aliment Pharmacol Ther. 2007;26(3):343–57.

Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23–34.

Wang B, Wang Y-H, Lv Z-F, Xiong H-F, Wang H, Yang Y, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20(2):79–88.

Li B-Z, Threapleton DE, Wang J-Y, Xu J-M, Yuan J-Q, Zhang C, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052.

Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.e14.

Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106(11):1970–5.

Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone sequential therapy for helicobacter pylori: a meta-analysis. Pharmacotherapy. 2015;35(8):719–30.

Park C-S, Lee S-M, Park C-H, Koh H-R, Jun C-H, Park S-Y, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109(10):1595–602.

Atehortua Rendon J, Pérez Cala T, Martínez A. Descripción de la resistencia de Helicobacter pylori a seis antibióticos de uso frecuente en Colombia. Rev Colomb de Gastroent. 2020;35(3):351-361.

Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection: Review: rifabutin for H. pylori infection. Aliment Pharmacol Ther. 2012;35(2):209–21.

Cheng H, Hu F-L. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol. 2009;15(7):860–4.

Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(7):802-7.e1.

Vincentini O, De Angelis I, Stammati A, Zucco F. Functional alterations induced by the food contaminant furazolidone on the human tumoral intestinal cell line Caco-2. Toxicol In Vitro. 1993;7(4):403–6.

Graham D, Lu H. Furazolidone in Helicobacter pylori therapy: Misunderstood and often unfairly maligned drug told in a story of French bread. Saudi J Gastroent. 2012;18(1).

Shah S, Iyer P, Moss S. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021;160(5):1831-1841.

Isaza C, Henao J, Martínez J, Arias J, Beltrán L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clinical Pharmacology. 2007;7(1).

Murakami M, Sakurai Y, Shiino M, Funao N, Nisimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439-46.

Nseir W, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A, et al. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. Aliment Pharmacol Ther. 2012;36(3):231–8.

Lau CSM, Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Infect Drug Resist. 2016;9:275–89.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–46.

Sezikli M, Çetinkaya ZA, Güzelbulut F, Yeşil A, Coşgun S, Kurdaş OÖ. Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori: Vitamin supplementation in the Helicobacter pylori treatment. J Clin Pharm Ther. 2012;37(3):282–5.

Descargas

Publicado

2021-10-29

Cómo citar

Zuluaga Arbelaez, N., Sierra-Vargas, E. C. ., Guevara-Casallas, L. G. ., & Pérez-Viana, S. . (2021). Estrategias terapéuticas para Helicobacter pylori en Colombia. CES Medicina, 35(3), 244–256. https://doi.org/10.21615/cesmedicina.6224

Número

Sección

Revisión de tema

Artículos más leídos del mismo autor/a